(Q31887862)

4 July 2017

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine (English)

1 reference

4 July 2017

C J Harrison

1

1 reference

4 July 2017

R L Miller

series ordinal

2

1 reference

4 July 2017

D I Bernstein

series ordinal

3

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

4 July 2017

1 reference

4 July 2017

19

1 reference

4 July 2017

1820-1826

1 reference

4 July 2017

13-14

1 reference

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time

4 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

New antiherpesvirus agents. Their targets and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Herpes simplex virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Herpesvirus vaccines. Development, controversies, and applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Herpes simplex virus glycoprotein treatment of recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

Low doses of interferon alpha result in more effective clinical natural killer cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

A species of human alpha interferon that lacks the ability to boost human natural killer activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900387-X

7 January 2021

10.1016/S0264-410X(00)00387-X

Identifiers

DOI

1 reference

4 July 2017

1 reference